These findings suggest TIMD4 targeting could not only directly inhibit tumour proliferation‐metastasis programs but also ameliorate immunosuppressive microenvironments through modulating immune checkpoint molecules like PD‐L1, thereby proposing potential combination strategies to counteract targeted therapy resistance [21]. The gene discussed is CD274; the disease is neoplasm.